Finastéride oral 1 mg face à Finastéride oral 0,2 mg

the increase in hair count (mean ___ SE) in the representative 1-inch diameter circular target area was similar (66 -+ 10.2 and 69 + 8.9 hairs, respectively)

Citation complémentaire (significativite)

At month 6, treatment with the 3 highest doses of finasteride tested (5, 1, and 0.2 mg) significantly increased hair count compared with baseline or placebo (P < .001; Table III; Figs 2 and 3)

Roberts JL, Fiedler V, Imperato-McGinley J et al.. Clinical dose ranging studies with finasteride, a type 2 5-alpha-reductase inhibitor, in men with male pattern hair loss. Journal of the American Academy of Dermatology 1999. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

and there was a numerically smaller increase for the 0.2 mg group (55 + 9.0 hairs)

Citation complémentaire (significativite)

At month 6, treatment with the 3 highest doses of finasteride tested (5, 1, and 0.2 mg) significantly increased hair count compared with baseline or placebo (P < .001; Table III; Figs 2 and 3)

Roberts JL, Fiedler V, Imperato-McGinley J et al.. Clinical dose ranging studies with finasteride, a type 2 5-alpha-reductase inhibitor, in men with male pattern hair loss. Journal of the American Academy of Dermatology 1999. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

At month 12, the finasteride 5, 1, and 0.2 mg groups demonstrated increases in hair count of 93 + 10, 85 + 11, and 65 --+- 13 hairs, respectively, from baseline (P < .001 vs placebo or 0.01 mg)

Roberts JL, Fiedler V, Imperato-McGinley J et al.. Clinical dose ranging studies with finasteride, a type 2 5-alpha-reductase inhibitor, in men with male pattern hair loss. Journal of the American Academy of Dermatology 1999. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

At month 12, the finasteride 5, 1, and 0.2 mg groups demonstrated increases in hair count of 93 + 10, 85 + 11, and 65 --+- 13 hairs, respectively, from baseline (P < .001 vs placebo or 0.01 mg)

Roberts JL, Fiedler V, Imperato-McGinley J et al.. Clinical dose ranging studies with finasteride, a type 2 5-alpha-reductase inhibitor, in men with male pattern hair loss. Journal of the American Academy of Dermatology 1999. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The percentages of patients rated as improved were comparable between the 5 and 1 mg groups (48% and 54%, respectively), but higher than the 0.2 mg group (38%)

Citation complémentaire (significativite)

At month 12, the finasteride 5, 1, and 0.2 mg groups demonstrated significant efficacy compared with placebo or 0.01 mg finasteride, and the 1 mg group was superior to the 0.2 mg group (P < .05)

Roberts JL, Fiedler V, Imperato-McGinley J et al.. Clinical dose ranging studies with finasteride, a type 2 5-alpha-reductase inhibitor, in men with male pattern hair loss. Journal of the American Academy of Dermatology 1999. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The percentages of patients rated as improved were comparable between the 5 and 1 mg groups (48% and 54%, respectively), but higher than the 0.2 mg group (38%)

Citation complémentaire (significativite)

At month 12, the finasteride 5, 1, and 0.2 mg groups demonstrated significant efficacy compared with placebo or 0.01 mg finasteride, and the 1 mg group was superior to the 0.2 mg group (P < .05)

Roberts JL, Fiedler V, Imperato-McGinley J et al.. Clinical dose ranging studies with finasteride, a type 2 5-alpha-reductase inhibitor, in men with male pattern hair loss. Journal of the American Academy of Dermatology 1999. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

At month 12, the investigator assessment demonstrated significant (P < .001) further improvement for the 5, 1, and 0.2 mg treatment groups, with percentages of patients rated as improved being higher than at month 6 (77%, 91%, and 81%, respectively)

Roberts JL, Fiedler V, Imperato-McGinley J et al.. Clinical dose ranging studies with finasteride, a type 2 5-alpha-reductase inhibitor, in men with male pattern hair loss. Journal of the American Academy of Dermatology 1999. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

At month 12, the investigator assessment demonstrated significant (P < .001) further improvement for the 5, 1, and 0.2 mg treatment groups, with percentages of patients rated as improved being higher than at month 6 (77%, 91%, and 81%, respectively)

Roberts JL, Fiedler V, Imperato-McGinley J et al.. Clinical dose ranging studies with finasteride, a type 2 5-alpha-reductase inhibitor, in men with male pattern hair loss. Journal of the American Academy of Dermatology 1999. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

5 mg 1 mg (n = 111) (n = 117) Patients with one or more 4 (3.6) 5 (4.3)

Roberts JL, Fiedler V, Imperato-McGinley J et al.. Clinical dose ranging studies with finasteride, a type 2 5-alpha-reductase inhibitor, in men with male pattern hair loss. Journal of the American Academy of Dermatology 1999. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

0.2 mg 0.01 mg Placebo 5 mg Placebo (n -- 115) (n = 117) (n = 233) (n = 111) (n = 116) 7 (6.1) 2 (1.7) 8 (3.4) 4 (3.6) 7 (6.0)

Roberts JL, Fiedler V, Imperato-McGinley J et al.. Clinical dose ranging studies with finasteride, a type 2 5-alpha-reductase inhibitor, in men with male pattern hair loss. Journal of the American Academy of Dermatology 1999. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Treatment with finasteride significantly decreased serum DHT levels at all doses (median decrease of -67.6% _+ 3.1%, -68.5% _+ 1.4%,-61.2% ___ 1.7%, and -10.8% _+ 4.2% for the 5, 1, 0.2, and 0.01 mg groups, respectively, at month 6; P < .01 vs placebo)

Roberts JL, Fiedler V, Imperato-McGinley J et al.. Clinical dose ranging studies with finasteride, a type 2 5-alpha-reductase inhibitor, in men with male pattern hair loss. Journal of the American Academy of Dermatology 1999. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Treatment with finasteride significantly decreased serum DHT levels at all doses (median decrease of -67.6% _+ 3.1%, -68.5% _+ 1.4%,-61.2% ___ 1.7%, and -10.8% _+ 4.2% for the 5, 1, 0.2, and 0.01 mg groups, respectively, at month 6; P < .01 vs placebo)

Roberts JL, Fiedler V, Imperato-McGinley J et al.. Clinical dose ranging studies with finasteride, a type 2 5-alpha-reductase inhibitor, in men with male pattern hair loss. Journal of the American Academy of Dermatology 1999. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).